Royalty Pharma (RPRX) EBT (2019 - 2026)

Royalty Pharma has reported EBT for 8 years, with the latest figure at $468.3 million in Q1 2026.

• Quarterly EBT rose 7.79% year-over-year to $468.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 23.2% YoY) and the FY2025 annual result came in at $1.3 billion, changed 0.5% from the prior year.
• EBT improved to $468.3 million in Q1 2026 per RPRX's latest filing, from $355.9 million in the prior quarter.
• Over five years, EBT peaked at $806.4 million in Q3 2024 and troughed at -$610.0 million in Q4 2022.
• A 5-year average of $297.3 million and a median of $351.3 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 1236.61% in 2022, then surged 10266.93% in 2025.
• Over 5 years, EBT stood at -$610.0 million in 2022, then soared by 217.63% to $717.6 million in 2023, then sank by 53.41% to $334.4 million in 2024, then gained by 6.45% to $355.9 million in 2025, then surged by 31.56% to $468.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $468.3 million, $355.9 million, and $444.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.